European journal of rheumatology最新文献

{"title":"Chondrocalcinosis and Osteoarthritis: A Literature Review.","authors":"Stacey Ying Guo, Cassandra A Lee, Barton L Wise","doi":"10.5152/eurjrheum.2023.21093","DOIUrl":"10.5152/eurjrheum.2023.21093","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to review the literature on associations between chondrocalcinosis (CC) and osteoarthritis (OA) and to examine the role of colchicine, previously established as effective for calcium pyrophosphate deposition disease, in the treatment of OA.</p><p><strong>Methods: </strong>A literature search for mechanistic and clinical studies published between 1990 and 2021 listed in PubMed was performed and studies were included if they examined the associations between OA and CC or colchicine using relevant search terms.</p><p><strong>Results: </strong>Published evidence suggests significant radiographic and mechanistic associations between knee OA and knee CC, but there are only a limited number of studies demonstrating associations between OA and CC in the hips, hands, and ankles. We examined three studies testing the efficacy of colchicine on treatment of pain in OA and found insufficient evidence to definitively establish that colchicine is effective to ameliorate symptoms of OA, although differences in study methodologies and inclusion criteria may explain inconsistent study findings.</p><p><strong>Conclusion: </strong>An association between CC and OA is supported at the knee joint in both radiographic and in-vitro studies, but is less definite when the relationship is evaluated at other joints, including at the hips, hands, and ankles. Further research is required to ascertain whether CC modifies symptoms in patients with osteoarthritis or is associated with OA progression. It may be worthwhile to further evaluate colchicine or other agents for potential symptom modifying roles in OA or in OA with CC.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9113047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Difference in OA: Should We Blame Estrogen?","authors":"Uyen-Sa D T Nguyen, Fiona R Saunders, Kathryn R Martin","doi":"10.5152/eurjrheum.2023.20193","DOIUrl":"10.5152/eurjrheum.2023.20193","url":null,"abstract":"<p><p>Osteoarthritis (OA) is a leading cause of chronic pain and disability, not only in the United States but also worldwide. The burden of OA is higher in women than in men. Estrogen as a possible explanation for observed sex differences in OA has not been definitively established. The purpose of this review was to summarize the results from studies of estrogen, estrogen depletion and treatment, and their impact on knee, hip, hand, and spine OA. We conducted a targeted review of the literature using PubMed. Although several studies show that hormone replacement therapy has the potential to be protective of OA for some joints, there are studies that showed no protective effect or even adverse effect. Taken together, the evidence for the protective effect of estrogen therapy depends on OA joint, OA outcome, and study design. Although this area has been studied for decades, more exclusively since the 1990s, there is a lack of high-quality experimental research in this topic. The lack of definitive conclusion on whether estrogen can play a role in the development in OA of either the knee, hip, spine, or hand is often in part due to the noncomparability of studies existing within the literature. Differences in diagnostic criteria, imaging modalities, populations studied, study designs, and outcome measures, as well as random error, have all contributed to inconclusive evidence. Future research on the role of estrogen in OA is needed, particularly as global demographic shifts in increasing overweight/obesity prevalence and ageing populations may contribute to widening OA-related health inequalities.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9113048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on the Article \"Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature\".","authors":"Alexandros A Drosos,&nbsp;Eleftherios Pelechas,&nbsp;Aliki I Venetsanopoulou,&nbsp;Paraskevi V Voulgari","doi":"10.5152/eurjrheum.2022.22055","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.22055","url":null,"abstract":"","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 1","pages":"49"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/ba/ejr-10-1-49.PMC10152112.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9771086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Musculoskeletal Point-of-Care Ultrasonography Training Among Canadian Postgraduate Rheumatology Programs.","authors":"Tenneille Tana,&nbsp;Noura Al Osaimi,&nbsp;Ummugulsum Gazel,&nbsp;Johannes Roth,&nbsp;Sibel Zehra Zehra Aydin,&nbsp;Susan Humphrey-Murto","doi":"10.5152/eurjrheum.2022.21081","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.21081","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the current state of musculoskeletal point-of-care ultrasonography training among the rheumatology postgraduate programs in Canada and explored the interest in developing a national curriculum.</p><p><strong>Method: </strong>A Canadian survey was developed by academic rheumatologists including point-of-care ultrasonography experts and point-of-care ultrasonography non-users. Across Canada, all 15 adult and 3 pediatric rheumatology English and French postgraduate programs were surveyed via Survey Monkey with a standardized questionnaire.</p><p><strong>Results: </strong>The completed response rates were 27% (24/89) for postgraduate year-4 and -5 rheumatology trainees and 61% (11/18) for program directors. Forty-two percent (10/24) of trainees had access to formal point-of-care ultrasonography training, and 67% (16/24) had some form of informal nonstructured exposure. Of all respondents, 87.5% (21/24) trainees and 82% (9/11) program directors agreed or strongly agreed that point-of-care ultrasonography is an important clinical tool in rheumatology. Eighty-nine percent (8/9) of program directors felt that point-of-care ultrasonography should be a formal part of rheumatology training.</p><p><strong>Conclusion: </strong>This national survey demonstrates that while musculoskeletal point-of-care ultrasonography is considered an important component of clinical practice, significant training barriers exist. The majority of both trainees and program directors felt that point-of-care ultrasonography should be a formal part of training and would be interested in a national standardized point-of-care ultrasonography curriculum in Canada.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 1","pages":"8-11"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/92/ejr-10-1-8.PMC10152115.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9400591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Camurati-Engelmann Disease: A Case-Based Review About an Ultrarare Bone Dysplasia.","authors":"Philipp Klemm,&nbsp;Iris Aykara,&nbsp;Uwe Lange","doi":"10.5152/eurjrheum.2023.21115","DOIUrl":"https://doi.org/10.5152/eurjrheum.2023.21115","url":null,"abstract":"<p><p>Camurati-Engelmann disease or progressive diaphyseal dysplasia is a rare hereditary disease that results in a symmetrical hyperostosis of the long bones (cortical thickening) and/or the base of the skull. Camurati-Engelmann disease is also associated with myopathy and neurological manifestations. Clinically, Camurati-Engelmann disease typically presents with bone pain in the lower extremities, muscle weakness, and a wobbly, stilted gait. The disease is caused by mutations in the transforming growth factor-beta 1 gene. Up to date, about 300 cases have been described in the literature. In this case-based review, we present the clinical picture and genetic and radiological findings in a 20-yearold male patient we diagnosed with Camurati-Engelmann disease and our considerations in his treatment and compare the case to the literature. The diagnosis of Camurati-Engelmann disease was confirmed on patients' history, clinical and radiological findings, and genetic testing for transforming growth factor beta-1 mutation. The patient responded well to single therapy with zoledronic acid. Early diagnosis leads to improved clinical outcomes and increased quality of life in affected patients.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 1","pages":"34-38"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/e7/ejr-10-1-34.PMC10152113.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9395600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) with postural orthostatic tachycardia syndrome after silicone breast implantation: Case report.","authors":"Jozélio Freire de Carvalho,&nbsp;Carolina Bonato Armond de Oliveira,&nbsp;Rogério Vilas Boas,&nbsp;Matheus Franklin Vicente Matias,&nbsp;Larissa Matos Carvalho Bastos","doi":"10.5152/eurjrheum.2022.21108","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.21108","url":null,"abstract":"<p><p>This study illustrates two patients who developed autoimmune/inflammatory syndrome induced by adjuvants (ASIA) with postural orthostatic tachycardia syndrome (POTS) after silicone breast implant (SBI) and improved after SBI extraction.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 1","pages":"23-25"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10848065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frosted Branch Angiitis in a Patient with Familial Mediterranean Fever Diagnosis.","authors":"Reşit Yıldırım,&nbsp;Mustafa Dinler,&nbsp;Ahmet Özer,&nbsp;Nazife Şule Yaşar Bilge,&nbsp;Timuçin Kaşifoğlu","doi":"10.5152/eurjrheum.2022.22018","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.22018","url":null,"abstract":"Corresponding author: Reşit Yıldırım E-mail: celeng18@gmail.com Received: March 18, 2022 Accepted: June 8, 2022 Publication Date: July 29, 2022 A 41-year-old female with a previous diagnosis of familial Mediterranean fever (FMF) was admitted due to a sudden-onset vision loss in the right eye during the third day of FMF attack. Past medical records revealed that she was non-compliant with her colchicine medication and therefore experienced 4 serositis attacks in the last 6 months. The systemic rheumatologic questionnaire was otherwise non-contributory. Ophthalmologic examination of the left eye demonstrated no pathology, whereas fundus evaluation of the right eye showed severe, white vascular sheaths extending from the optic disc to the periphery and preand intra-retinal hemorrhages in all retinal quadrants (Figure 1). Dilated and tortuous veins were detected in fluorescent angiography imaging (Figure 2). Based on these findings, a diagnosis of frosted branch angiitis (FBA) was made. Laboratory investigations were unremarkable except for mild elevations of acute phase parameters. Serologic studies for antinuclear antibody, anticardiolipin antibodies, and antineutrophil cytoplasmic antibodies (ANCA) were negative. Possible infectious agents were also excluded, and extensive radiographic evaluation of the central nervous system was non-revealing. After excluding all other possibilities, a diagnosis of FBA possibly related to FMF was considered and a combination of methylprednisolone (1 mg/kg/day) with tapering doses, azathioprine (2.5 mg/kg/day) and colchicine (0.5 mg, 3 times daily), was initiated. The visual complaints in the right eye completely resolved at the end of the third month. In the fourth month of follow-up, she manifested with sudden-onset vision loss in the same eye during a serositis attack. Colchicine dosage was escalated to 4 times a day with concomitant moderate steroid administration. She is currently on colchicine and azathioprine without any FMF attack and relapses of FBA in the last 6 months","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 1","pages":"47-48"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/be/ejr-10-1-47.PMC10152073.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9407322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging the Enthesopathy and Manipulating the Fascia: Ultrasound is the \"Sous Chef\".","authors":"Carmelo Pirri,&nbsp;Carla Stecco,&nbsp;Nina Pirri,&nbsp;Raffaele De Caro,&nbsp;Levent Özçakar","doi":"10.5152/eurjrheum.2022.21208","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.21208","url":null,"abstract":"pain","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 1","pages":"45-46"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f0/6c/ejr-10-1-45.PMC10152078.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9401089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriatic Arthritis: Differential Features at the Time of Clinical Presentation in a Large Cohort of Patients with Polyarthralgia.","authors":"Santiago Ruta,&nbsp;Rosario Jaldin Cespedes,&nbsp;Laura Cuellar,&nbsp;Jonatan Mareco,&nbsp;Darío Aguerre,&nbsp;Rodrigo García Salinas","doi":"10.5152/eurjrheum.2022.22035","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.22035","url":null,"abstract":"<p><strong>Objective: </strong>Most patients with psoriatic arthritis begin with cutaneous psoriasis, which is why all early detection strategies are based on screening in the dermatological consultation and referral to a rheu matologist. However, there are cases of patients who consult initially for musculoskeletal symptoms, mostly joint pain, regardless of family and/or personal history of psoriasis. This study aimed to esti mate the frequency of psoriatic arthritis in a cohort of patients who consulted for polyarthralgia and to determine the differential features, at the time of clinical presentation, in relation to both patients with final diagnosis other than psoriatic arthritis and patients with diagnosis of rheumatoid arthritis.</p><p><strong>Methods: </strong>Consecutive patients with polyarthralgia (including arthralgia of the hands) were included. Clinical examination, laboratory tests, ultrasound with power Doppler of both hands, and radiography of both hands and feet were performed at baseline. All patients were followed up and the definitive diagnosis of psoriatic arthritis was established.</p><p><strong>Results: </strong>A total of 1055 were included, 88 (8.3%) ended with diagnosis of psoriatic arthritis. Diagnosis of psoriatic arthritis was positively associated with a family history of psoriasis (odds ratio=4.14), pso riasis (odds ratio=78.94), radiographic erosions (odds ratio=5.74), and ultrasound with at least 1 joint with positive power Doppler (odds ratio=7.11). In comparison with rheumatoid arthritis patients, diagnosis of psoriatic arthritis was positively associated with psoriasis (odds ratio=433.42) and family history of psoriasis (odds ratio=41.63). On the other hand, it was negatively associated with positivity, for both rheumatoid factor (odds ratio=0.03) and anti-cyclic citrullinated peptide antibodies (odds ratio=0.06).</p><p><strong>Conclusion: </strong>The frequency of psoriatic arthritis was 8.3% and was associated with a personal and/or family history of psoriasis, radiographic erosions, and inflammatory involvement by Power Doppler Ultrasound (PDUS). In comparison with rheumatoid arthritis patients, psoriatic arthritis was associated with a personal and/or family history of psoriasis, while the presence of both rheumatoid factor and/ or anti-cyclic citrullinated peptide antibodies was shown to be a protective factor for the diagnosis of psoriatic arthritis.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 1","pages":"12-17"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/35/61/ejr-10-1-12.PMC10152075.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9771090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Infections in Patients Treated with Tocilizumab for Systemic Diseases Other Than Rheumatoid Arthritis: A Retrospective Multicenter Observational Study.","authors":"Florent Broca,&nbsp;Odile Souchaud-Debouverie,&nbsp;Evelyne Liuu,&nbsp;Pascal Roblot,&nbsp;Mickaël Martin","doi":"10.5152/eurjrheum.2022.22028","DOIUrl":"https://doi.org/10.5152/eurjrheum.2022.22028","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to describe severe infections in patients treated with tocilizumab for systemic diseases other than rheumatoid arthritis.</p><p><strong>Methods: </strong>Data from patients receiving at least 2 doses of tocilizumab for systemic diseases other than rheumatoid arthritis between January 1, 2012, and July 1, 2020, in the region Poitou-Charentes (France) were retrospectively collected from medical records. Psoriatic arthritis and systemic juvenile idiopathic arthritis were also excluded as usually treated with similar modalities to rheumatoid arthritis.</p><p><strong>Results: </strong>Of 37 patients, mainly suffering from giant cell arteritis, 25 patients (68%) had at least 1 infectious event and 15 severe infections occurred in 6 patients (3.2/100 patient-years), mainly bacterial. Lower respiratory tract and skin were the main sites. Severe bacterial infections were associated with a marked biological inflammatory syndrome, even under a cycle of administration of tocilizumab. Two severe zonas and 1 severe diverticulitis occurred. No tuberculosis or viral hepatitis reactivation was observed.</p><p><strong>Conclusion: </strong>The incidence rate of severe infections was 3.2/100 patient-years and seems lower than that reported in rheumatoid arthritis. C-reactive protein dosage could be helpful for the diagnosis of bacterial infectious adverse events in patients on tocilizumab. Further larger studies are needed to confirm these results to assess potential risk factors for severe infections.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 1","pages":"18-22"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/c4/ejr-10-1-18.PMC10152110.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9401492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}